27239541|t|Function and clinical meaningfulness of treatments for mild Alzheimer's disease
27239541|a|Effectiveness of Alzheimer's disease (AD) treatments is commonly evaluated with coprimary outcomes; cognition with function to ensure clinical meaningfulness of a cognitive effect. We reviewed the literature for functional outcomes in mild AD or mild cognitive impairment (MCI) patients (distinct from combined mild-moderate / severe AD) treated with approved AD drugs. Cognitive and functional treatment differences in mild AD patients in solanezumab EXPEDITION / EXPEDITION2 studies were compared across time. Seven publications provided MCI / mild AD functional outcomes, one of which reported a significant functional treatment effect. Secondary analyses of EXPEDITION studies suggested a smaller functional effect of solanezumab relative to cognition. An increasing effect of solanezumab over 18 months was shown for cognition and function. Function as the sole measure to demonstrate clinical meaningfulness of cognitive effects in mild AD may have limitations. For disease - modifying treatments, point differences on cognitive and functional scales should be qualified with duration of treatment.
27239541	0	8	Function	T041	C0563143
27239541	13	21	clinical	T080	C0205210
27239541	22	36	meaningfulness	T080	C1280519
27239541	40	50	treatments	T061	C0087111
27239541	55	59	mild	T080	C2945599
27239541	60	79	Alzheimer's disease	T047	C0002395
27239541	80	93	Effectiveness	T080	C1280519
27239541	97	116	Alzheimer's disease	T047	C0002395
27239541	118	120	AD	T047	C0002395
27239541	122	132	treatments	T061	C0087111
27239541	160	178	coprimary outcomes	T169	C1274040
27239541	180	189	cognition	T041	C0009240
27239541	195	203	function	T041	C0563143
27239541	214	222	clinical	T080	C0205210
27239541	223	237	meaningfulness	T080	C1280519
27239541	243	252	cognitive	T041	C0009240
27239541	253	259	effect	T080	C1280500
27239541	264	272	reviewed	T080	C1709940
27239541	277	287	literature	T170	C0023866
27239541	292	302	functional	T041	C0563143
27239541	303	311	outcomes	T169	C1274040
27239541	315	319	mild	T080	C2945599
27239541	320	322	AD	T047	C0002395
27239541	326	351	mild cognitive impairment	T048	C1270972
27239541	353	356	MCI	T048	C1270972
27239541	358	366	patients	T101	C0030705
27239541	391	404	mild-moderate	T080	C1299392
27239541	407	413	severe	T080	C0205082
27239541	414	416	AD	T047	C0002395
27239541	418	430	treated with	T061	C0332293
27239541	440	442	AD	T047	C0002395
27239541	443	448	drugs	T121	C0013227
27239541	450	459	Cognitive	T061	C0009244
27239541	464	474	functional	T041	C0563143
27239541	475	484	treatment	T061	C0087111
27239541	500	504	mild	T080	C2945599
27239541	505	507	AD	T047	C0002395
27239541	508	516	patients	T101	C0030705
27239541	520	531	solanezumab	T116,T121,T129	C2935150
27239541	532	542	EXPEDITION	T052	C0015315
27239541	545	556	EXPEDITION2	T052	C0015315
27239541	557	564	studies	T062	C2603343
27239541	570	578	compared	T052	C1707455
27239541	586	590	time	T079	C0040223
27239541	598	610	publications	T073,T170	C0034036
27239541	620	623	MCI	T048	C1270972
27239541	626	630	mild	T080	C2945599
27239541	631	633	AD	T047	C0002395
27239541	634	644	functional	T041	C0563143
27239541	645	653	outcomes	T169	C1274040
27239541	691	701	functional	T041	C0563143
27239541	702	718	treatment effect	T033	C1518681
27239541	720	738	Secondary analyses	UnknownType	C0683944
27239541	742	752	EXPEDITION	T052	C0015315
27239541	753	760	studies	T062	C2603343
27239541	781	791	functional	T041	C0563143
27239541	792	798	effect	T080	C1280500
27239541	802	813	solanezumab	T116,T121,T129	C2935150
27239541	826	835	cognition	T041	C0009240
27239541	840	850	increasing	T169	C0442808
27239541	851	857	effect	T080	C1280500
27239541	861	872	solanezumab	T116,T121,T129	C2935150
27239541	881	887	months	T079	C0439231
27239541	902	911	cognition	T041	C0009240
27239541	916	924	function	T041	C0563143
27239541	926	934	Function	T041	C0563143
27239541	947	954	measure	T081	C0079809
27239541	970	978	clinical	T080	C0205210
27239541	979	993	meaningfulness	T080	C1280519
27239541	997	1006	cognitive	T041	C0009240
27239541	1007	1014	effects	T080	C1280500
27239541	1018	1022	mild	T080	C2945599
27239541	1023	1025	AD	T047	C0002395
27239541	1035	1046	limitations	T169	C0449295
27239541	1052	1059	disease	T047	C0012634
27239541	1062	1071	modifying	T169	C0392747
27239541	1072	1082	treatments	T061	C0087111
27239541	1105	1114	cognitive	T041	C0009240
27239541	1119	1129	functional	T041	C0563143
27239541	1130	1136	scales	T170	C0349674
27239541	1162	1183	duration of treatment	T079	C0444921